Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Acquires $138,859.50 in Stock
Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Wayne D. Mackie bought 42,726 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was acquired at an average price of $3.25 per share, for a total transaction of $138,859.50. Following the transaction, the director now owns 161,290 shares of the company’s stock, valued at $524,192.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
NASDAQ:ORGO opened at $5.08 on Friday. The stock’s 50-day moving average is $4.03 and its 200-day moving average is $3.92. The company has a current ratio of 1.78, a quick ratio of 1.35 and a debt-to-equity ratio of 2.95. The stock has a market cap of $547.55 million, a P/E ratio of -13.73 and a beta of 1.33. Organogenesis Holdings Inc. has a 1-year low of $2.47 and a 1-year high of $7.01.
Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.19 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.27. Organogenesis had a negative return on equity of 101.41% and a negative net margin of 13.58%. As a group, equities analysts forecast that Organogenesis Holdings Inc. will post -0.36 EPS for the current year.
A number of research firms have issued reports on ORGO. Zacks Investment Research upgraded Organogenesis from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Wednesday, October 14th. Oppenheimer restated a “buy” rating and set a $9.00 price target on shares of Organogenesis in a report on Monday, September 21st. SVB Leerink boosted their price target on Organogenesis from $9.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday. BidaskClub cut Organogenesis from a “hold” rating to a “sell” rating in a report on Friday, September 25th. Finally, Credit Suisse Group boosted their price target on Organogenesis from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Tuesday, November 10th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $8.30.
Organogenesis Company Profile
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Read More: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.